Company signals · Biotech & Pharma
Gilead Sciences
3 signals in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: The wider read — a Talent Market Index of 112.8 (Hot), up 11.4 month-on-month — shows Asia signal flow rising (+3.1pts).
Gilead Sciences: 2 signals in the last 90 days — above the Biotech & Pharma median of 1 across 23 tracked companies; 0.3% of MitchelLake's Asia signal flow; 3 tracked across 62 days.
Signals at Gilead Sciences
Ma Activity
AmericasGilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
Leadership read: Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in biotech & pharma.
curated · 2026-05-25 · context →
Ma Activity
EMEAGilead Sciences acquired Tubulis, a Germany-based clinical-stage biotechnology company for up to USD 5.0 billion
Leadership read: Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in biotech & pharma.
curated · 2026-04-07 · context →
Ma Activity
AsiaGilead Sciences agreed to acquire Ouro Medicines for up to $2.18 billion, gaining rights to antibody drug licensed from China's Keymed Biosciences
Leadership read: Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in biotech & pharma.
curated · 2026-03-24 · context →
More signals across Biotech & Pharma
Geographic Expansion · Asia
Thermo Fisher Scientific →Thermo Fisher Scientific's Manila Shared Services Centre is scaling rapidly from 100 to ~700 employees by 2026, positioning itself as a high-impact regional hub for Asia-Pacific operations with focus on digital transformation and strategic value creation beyond cost efficiency.
Capital Raising · Asia
Legend Biotech →First Beijing Investment Ltd acquired $43.78 million stake (2.3M shares) in Legend Biotech, a cancer cell therapy developer
Geographic Expansion · Asia
Promomed Group →Promomed Group (Russian pharmaceutical company) is expanding into Vietnam's pharmaceutical market with strategic partnerships. Founder Petr Bely met with Vietnam's Minister of Health to discuss long-term cooperation, technology transfer, and manufacturing operations targeting innovative drugs, biosimilars, and monoclonal antibodies
Partnership · Asia
Bristol Myers Squibb →Bristol Myers Squibb partners with China's Hengrui Pharma on a $15.2 billion deal to advance more than a dozen early-stage drugs
Ma Activity · Americas
Biogen →Biogen acquired Apellis Pharmaceuticals for $5.6B and subsequently paused or canceled the majority of research programs that came with the acquisition, laying off a small number of employees from Apellis.
Ma Activity · Americas
Bora Pharmaceuticals →Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.
Intelligence powered by Autonodal ↗